The Survivor

Rooftops and billboards may be more important than hefty infrastructure.

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

Goldman Sachs said this week there are plenty of top tech companies to buy heading into their quarterly results.

Apple stock is trading near record highs and closing in on Nvidia’s market cap. Portfolio manager Jeff Kilburg explains what’s driving the rally and why he thinks the momentum could continue.

The S&P 500 has struggled to break decisively above 7,800 since first reaching that area in late July.

Cerebras has lost roughly 72% of its value since its peak, but contrarian tech investor Paul Meeks says its AI technology and massive backlog could fuel a comeback.

U.S. Treasurys are returning to favor as a safe haven play that sidesteps investors’ worries over a shaky economy and the future of the data center build-out.

PhillipCapital moved its rating on the Elon Musk giant to buy from sell, with the bullishness stemming from the company’s AI business.

A bout of volatility has hit the price of municipal bonds, but there are solid buying opportunities available — including one high-yielding corner.

The Nasdaq Composite dropped 2.6% on Thursday as worries over spending on artificial intelligence ramped up.